Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...
Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford ...
Loại thuốc thế hệ mới CagriSema được thử nghiệm mới đấy có khả năng mang lại hiệu quả giảm cân đáng kể cho bệnh nhân thừa cân ...
Novo Nordisk A/S is following in rival Eli Lilly & Co.’s footsteps by selling its hit weight-loss drug Wegovy directly to US patients at a discount. The Danish drugmaker launched NovoCare ...
Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...
Novo Nordisk is cutting the price of its weight-loss drug Wegovy to $499 per month for cash-paying customers who buy through its NovoCare Pharmacy. The discounted price is aimed at uninsured ...
Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time frame ...